Phase 3
N=47
Evaluation of the Bio-Seal Biopsy Track Plug
Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00527722 ↗Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: Number of Participants With Absence of Pneumothoraces — 18; 18 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Bio-Seal Track Plug (Device); No lung plug (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- M.D. Anderson Cancer Center
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Absence of Pneumothoraces |
18; 18 | — |
Summary
The purpose of this study is to demonstrate safety and effectiveness of the Bio-Seal Biopsy Track Plug in a clinical setting for use in lung biopsy procedures to reduce the rate of air leaks, commonly associated with the procedure. The Bio-Seal System is cleared in the U.S. with an indication for use as a lung biopsy site marker.
Eligibility Criteria
Inclusion Criteria
- The patient, or legal representative, must understand and provide written consent for the procedure
- The patient has a non-calcified, radiologically suspicious opacity or lung nodule, including a metastatic lung module, or mass of at least 1.0 cm in size; as determined by CT scan equipped with measurement software. Suspicious nodules observed by CT scan are defined as non-calcified masses with convex borders, not known to be stable. Suspicious nodules can also be defined as masses demonstrating opacity on x-ray that are suspicious by radiographic or clinical means and require biopsy.
- The patient must meet all medical conditions for lung biopsy;
- The patient must be at least 18 years of age;
Exclusion Criteria
- Patients with radiological findings of bullous emphysema, and the bullae are located near the intended area for biopsy. (Patients may enter the study who have radiological findings of bullous emphysema, as long as the cysts, blebs, or bullae are not in the area of the anticipated biopsy, and biopsy needle track).
- Female patients who are pregnant. Note: patients of childbearing potential should have a pregnancy test no more than one week prior to the biopsy procedure, and be instructed to have no unprotected sexual intercourse after the test until the biopsy procedure is completed
- Patients who are uncooperative or cannot follow instructions
- Patients who are currently enrolled in another Investigational New Drug (IND) or Device Exemption (IDE) clinical investigation that has not completed the required follow-up period
- Patients who cannot tolerate mild sedation, possibly secondary to poor respiratory status;
- Patients with fungal infections (Patients with known or imaging evidence highly suggestive of pulmonary fungal infection)
Data sourced from ClinicalTrials.gov (NCT00527722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.